tiprankstipranks
Origin Therapeutics Holdings, Inc. (TSE:SPLY)
CNQX:SPLY
Canadian Market

Origin Therapeutics Holdings, Inc. (SPLY) Income Statement

2 Followers

Origin Therapeutics Holdings, Inc. Income Statement

Last quarter (Q1 2024), Origin Therapeutics Holdings, Inc.'s total revenue was C$―, a decrease of ― from the same quarter last year. In Q1, Origin Therapeutics Holdings, Inc.'s net income was C$-1.03M. See Origin Therapeutics Holdings, Inc.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Sep 23Sep 22Sep 21
Total Revenue
---C$ 0.00
Cost of Revenue
----
Gross Profit
----
Operating Expense
C$ 3.32MC$ 6.32MC$ 1.21MC$ 1.19M
Operating Income
C$ -3.32MC$ -6.32MC$ -1.21MC$ -1.19M
Net Non Operating Interest Income Expense
C$ 29.16KC$ 9.49KC$ 25.01KC$ 59.00
Other Income Expense
C$ 56.20K-C$ 290.19KC$ 341.70K
Pretax Income
C$ -3.58MC$ -6.31MC$ -1.45MC$ -845.51K
Tax Provision
----
Earnings From Equity Interest Net Of Tax
----
Net Income Common Stockholders
C$ -3.58MC$ -6.31MC$ -1.45MC$ -845.51K
Basic EPS
C$ -0.04C$ -0.20C$ -0.03C$ -0.01
Diluted EPS
C$ -0.04C$ -0.20C$ -0.03C$ -0.01
Basic Average Shares
C$ 202.28MC$ 31.12MC$ 56.56MC$ 56.56M
Diluted Average Shares
C$ 202.28MC$ 31.12MC$ 56.56MC$ 56.56M
Dividend Per Share
----
Total Operating Income As Reported
----
Reported Normalized Basic E P S
----
Reported Normalized Diluted E P S
----
Rent Expense Supplemental
----
Total Expenses
C$ 2.52MC$ 6.32MC$ 1.21MC$ 1.19M
Net Income From Continuing And Discontinued Operation
C$ -3.58MC$ -6.31MC$ -1.45MC$ -845.51K
Normalized Income
C$ -3.29MC$ -4.64MC$ -1.07MC$ -1.19M
Interest Expense
----
EBIT
C$ -3.58MC$ -6.31MC$ -1.45MC$ -1.19M
EBITDA
C$ -3.58MC$ -6.31MC$ -1.45MC$ -1.19M
Currency in CAD

Origin Therapeutics Holdings, Inc. Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis